ArticlePloS one2021
Rapid detection of multidrug-resistant tuberculosis based on allele-specific recombinase polymerase amplification and colorimetric detection.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Isothermal nucleic acid amplification techniques: A comprehensive overview on their principle & applications as alternative to PCR.Practical laboratory medicine · 2026Review
- An integrated complete-genome sequencing and systems biology approach to predict antimicrobial resistance genes in the virulent bacterial strains of Moraxella catarrhalis.Briefings in functional genomics · 2026Article
- Recombinase polymerase amplification for single nucleotide polymorphism-specific detection of βAnalytical biochemistry · 2025Article
- Development of SNP-LAMP Combined with Lateral Flow Dipstick to Detect the S531LDiagnostics (Basel, Switzerland) · 2025Article
- A streamlined CRISPR-based test for tuberculosis detection directly from sputum.Science advances · 2025Article
- Rapid visual detection of bovine viral diarrhea virus (BVDV) using recombinase polymerase amplification with SYBR green I.BMC veterinary research · 2025Article
- Peptide nucleic acid-immobilised paper combined with multiplex recombinase polymerase amplification for the ultrasensitive and rapid detection of rifampicin-resistant tuberculosis.Scientific reports · 2025Article
- A duplex one-step recombinase aided PCR assay for the rapid and sensitive detection of the isoniazid resistance genes katG and inhA inFrontiers in microbiology · 2025Article
- Association Between Diabetes Mellitus-Tuberculosis and the Generation of Drug Resistance.Microorganisms · 2024Review
- A multiplexed, allele-specific recombinase polymerase amplification assay with lateral flow readout for sickle cell disease detection.Lab on a chip · 2024Article
- Simultaneous detection of bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 (BoHV-1) using recombinase polymerase amplification.Scientific reports · 2024Article
- Single-Drop Blood Detection of CommonACS omega · 2023Article
- An integrated complete-genome sequencing and systems biology approach to predict antimicrobial resistance genes in the virulent bacterial strains of Moraxella catarrhalis.Briefings in functional genomics · 2023Article
- Advances in point-of-care genetic testing for personalized medicine applications.Biomicrofluidics · 2023Review
- Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics.Tuberculosis (Edinburgh, Scotland) · 2023Review
- Rapid detection of Mycobacterium tuberculosis using recombinase polymerase amplification: A pilot study.PloS one · 2023Article
- Development of a Real-Time Recombinase-Aided Amplification Method to Rapidly Detect Methicillin-ResistantMicroorganisms · 2022Article
- From saliva to SNP: non-invasive, point-of-care genotyping for precision medicine applications using recombinase polymerase amplification and giant magnetoresistive nanosensors.Lab on a chip · 2022Article
- Recent advances in recombinase polymerase amplification: Principle, advantages, disadvantages and applications.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant tuberculosis (MDR-TB) poses a serious threat to TB control. Early diagnosis and proper treatment are essential factors to limit the spread of the disease. The existing molecular tests for MDR-TB usually require specific instruments, steady power supply, and routine maintenance, which might be obstacles for low-resource settings. This study aimed to develop allele-specific isothermal recombinase polymerase amplification (allele-specific RPA) to simultaneously detect the most common mutations in the rpoB gene at codons 516, 526, and 531, which are associated with rifampicin resistance, and in the katG gene at codon 315, which is related to isoniazid resistance. Allele-specific primers targeting four major mutations, rpoB516, rpoB526, rpoB531, and katG315, were constructed and used in individual RPA reactions. The RPA amplicons were endpoints detected by the naked eye immediately after applying SYBR Green I. The optimised RPA assay was evaluated with the Mycobacterium tuberculosis wild-type strain H37Rv and 141 clinical M. tuberculosis isolates. The results revealed that allele-specific RPA combined with SYBR Green I detection (AS-RPA/SYBR) detected these four major mutations with 100% sensitivity and specificity relative to DNA sequencing. The limits of detection for these particular mutations with AS-RPA/SYBR were 5 ng. As a result of the outstanding performance of AS-RPA/SYBR, including its easy setup, speed, lack of a specific instrument requirement, and lack of cross-reaction with other bacteria, this technique may be integrated for the molecular diagnosis of MDR-TB, especially in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.